Try our Advanced Search for more refined results

April 12, 2021

Xu v. FibroGen, Inc. et al

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. January 31, 2024

    FibroGen's $28.5M Deal With 30K Investors Nears Tentative OK

    A California federal judge indicated Wednesday that he'll preliminarily sign off on a $28.5 million settlement secured for a class of approximately 30,000 FibroGen investors who accused the company of making misleading statements about the safety of its anemia drug, citing the risk of recoverability issues due to FibroGen's financial state.

2 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!